Compare Revvity Inc (RVTY) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Under Armour Inc Class A — how do they compare? Revvity Inc trades at $154.49 (market cap $16.98B), while Under Armour Inc Class A trades at $4.81 (market cap $2.07B). The key difference: Revvity Inc is far larger — about 8.2× Under Armour Inc Class A's market cap, and Revvity Inc pays a 0.18% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Under Armour Inc Class A for 18 Days on average.
| RVTY | UA | |
|---|---|---|
Market Cap | $16.98B | $2.07B |
Volume | 1,456,900 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $7.88 |
52-Week Low | $82.26 | $3.96 |
Typical Hold Time | 12 Days | 18 Days |
Enterprise Value | $19.30B | $3.05B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Under Armour (UA) trades at $4.75, up 1.06% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability metrics, including a -9.99% net income margin. Cash flow remains negative at -$362M for 2025, while analyst consensus shows 40% buy ratings amid ongoing operational challenges.
Outlook remains cautious with revenue guidance cuts and competitive pressures. Investment opportunity exists if turnaround strategies succeed, but risks include sustained negative cash flow, weak consumer demand, and high debt levels. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
